X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EDG-5506 (sevasemten) is an investigational orally administered small molecule, MYH4 inhibitor. It is being developed for the treatment of becker & duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
EDG-5506 (sevasemten) is an orally administered small molecule designed to prevent contraction-induced muscle damage. Currently is being evaluated in clinical trials for the treatment of Duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
EDG-5506 is an investigational orally administered small molecule, MYH4 inhibitor. It is being developed for the treatment of duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
Edgewise intends to use the net proceeds to support the potential U.S. commercial launch of EDG-5506 (sevasemten), an orally administered skeletal myosin inhibitor, in patients with Becker muscular dystrophy and completion of a Phase 3 trial with EDG-5506 in Duchenne.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2024
Details:
EDG-5506 is a small molecule tablet which works by inhibiting Myosin ATPase, it is currently being investigated in adults for treating Becker Muscular Dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator that is advancing in a Phase 1 trial. The compound is designed to slow early contraction velocity and improve impaired cardiac relaxation.
Lead Product(s): EDG-7500
Therapeutic Area: Cardiology/Vascular Diseases Product Name: EDG-7500
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medpace, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
EDG-7500 is an investigational first-in-class oral, selective, sarcomere modulator for hypertrophic cardiomyopathy. The compound is designed to slow contraction velocity and improve impaired cardiac relaxation, hallmarks of HCM.
Lead Product(s): EDG-7500
Therapeutic Area: Cardiology/Vascular Diseases Product Name: EDG-7500
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
